Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 8
HOS-147518 · Präparat HOS-099678
In the Phase 3 trial B7471014 (Study 1014), 831 participants 15 months to less than 18 years of age received a single dose of Prevenar 20 in 4 age groups (209 participants 15 to less than 24 months of age; 216 participants 2 years to less than 5 years of age; 201 participants 5 years to less than 10 years age; and 205 participants 10 years to less than 18 years of age). The participants less than 5 years of age had received at least 3 prior doses of Prevenar 13.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage f09aaab498ce85806b623c7f1d2f6899818efb813d0526d1659dc3902802c2da · Zeichen 3944–4410 im Abschnitt